Table 3.

Comparison of the Incidence of Rebound Hyperglycemia by Group

Variable	Before propensity score matching		After propensity score matching
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Univariable
Groupa	0.20 (0.09–0.42)	<0.001b	0.19 (0.07–0.47)	<0.001b
Multivariable
Groupa	0.16 (0.06–0.43)	<0.001b	0.14 (0.04–0.47)	0.001b
Age	0.99 (0.96–1.02)	0.499	0.99 (0.95–1.03)	0.480
Body mass index, kg/m2	1.10 (0.98–1.26)	0.146	1.14 (0.96–1.35)	0.132
Classification (DKA)	0.72 (0.17– 2.99)	0.648	0.38 (0.06–2.45)	0.306
Classification (HHS)	0.97 (0.24–3.89)	0.969	0.95 (0.16–5.73)	0.952
Classification (DKA with ketoacidosis)	0.53 (0.15–1.94)	0.339	0.55 (0.10–3.18)	0.507
Dose of basal insulin, U	1.10 (0.97–1.25)	0.155	1.09 (0.95–1.27)	0.223
Duration of CIII, hr	0.98 (0.96–1.00)	0.064	0.98 (0.96–1.00)	0.081
Glucose level immediately before CIII discontinuation, mg/dL	1.02 (1.01–1.03)	0.005b	1.02 (1.00–1.03)	0.049b
Duration of DM, yr	1.00 (0.95–1.06)	0.876	1.00 (0.93–1.08)	0.942
Precipitating factor	2.30 (0.80–6.57)	0.120	2.10 (0.58–7.58)	0.258
OHA (metformin)	1.15 (0.34–3.93)	0.181	2.32 (0.47–11.48)	0.304
OHA (sulfonylurea)	1.13 (0.34–3.71)	0.842	0.59 (0.12–2.85)	0.512
OHA (DPP4 inhibitor)	0.46 (0.13–1.65)	0.231	0.29 (0.05–1.57)	0.151
OHA (SGLT2 inhibitor)	0.89 (0.13–5.98)	0.906	2.56 (0.26–25.6)	0.425

CI, confidence interval; DKA, diabetic ketoacidosis; HHS, hyperosmolar hyperglycemic state; CIII, continuous intravenous insulin infusion; DM, diabetes mellitus; OHA, oral hypoglycemic agent; DPP4, dipeptidyl peptidase 4; SGLT2, sodium/glucose cotransporter 2.

^aEarly vs. delayed basal insulin group;

^bValues are statistically significant (P<0.05) by logistic regression analyses.